Arzerra (ofatumumab) is indicated in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed Chronic Lymphocytic Leukemia (CLL).

INN:

Subtype:

Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)

License:

FDA

Class:

CD20 MAb

R/R

PIhttps://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/arzerra.pdf 

1. Approved Labelling 

Arzerra (ofatumumab) is indicated in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed Chronic Lymphocytic Leukemia (CLL).

2. Treatment Regimen

  • Dilute and administer as an intravenous infusion. Do not administer as an intravenous push or bolus.

The recommended dosage and schedule in combination with fludarabine and cyclophosphamide is:

  • 300 mg on Day 1, followed 1 week later by 1,000 mg on Day 8 (Cycle 1), followed by 1,000 mg on Day 1 of subsequent 28-day cycles for a maximum of 6 cycles.

For initial 300-mg dose: Initiate infusion at a rate of 3.6 mg/hour (12 mL/hour).

For subsequent infusions of 1,000 mg: Initiate infusion at a rate of 25 mg/hour (25 mL/hour). Initiate infusion at a rate of 12 mg/hour if a Grade 3 or greater infusion-related adverse event was experienced during the previous infusion.

Pre-medicate with oral acetaminophen, oral or intravenous antihistamine, and intravenous corticosteroid.

3. AE/Warnings

Please see section 5 of the PI.



All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.